We’re excited to announce the expansion of our strategic partnership with global healthcare leader Novo Nordisk under a framework agreement that initially is contemplated to run over five years.
Novo Nordisk and Ginkgo have created a flexible and scalable new model for their R&D partnership. Together, we aim to improve the manufacturing of Novo Nordisk’s medicines for serious chronic diseases, including diabetes and obesity medications. We also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk’s portfolio.
“We have been very pleased with the progress made in our initial work with Ginkgo focused on exploring strategies for a more effective future production process. We look forward to leveraging Ginkgo’s synthetic biology platform across our R&D pipeline, from discovery through new ways of manufacturing, in this broader strategic partnership. Moreover, we are eager to explore more flexible models for external partnerships and this agreement allows Novo Nordisk to start more projects with Ginkgo in a faster and more agile manner.”
Marcus Schindler, Novo Nordisk EVP and CSO
Novo Nordisk has played an important role in shaping the landscape for pharmaceutical products in the 21st century. We’re so excited to expand our partnership to help them achieve their ambitious and global goals. With this deal structure, Novo Nordisk can easily access the entire expanse of Ginkgo’s pharma services from discovery through manufacturing. Our teams share a deep passion for discovering, developing, and manufacturing innovative therapeutics for serious chronic diseases that affect billions of people around the world. We are honored to work shoulder-to-shoulder with the brilliant scientists, engineers, and developers at Novo Nordisk to help change disease outcomes for patients around the world.
